Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.56 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 6/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4341766 | 0.83 | CNR2 (0.55) | CNR2HTR4RORCCNR1 | |
| SCHEMBL13578220 | 0.82 | CNR2 (0.59) | CNR2HTR4RORCCNR1 | |
| SCHEMBL4334827 | 0.80 | CNR2 (0.53) | CNR2SSTR4HTR4RORCCNR1 | |
| Trifluoroacetic Acid SCHEMBL4320381 | 0.79 | CNR2 (0.51) | CNR2HTR4RORC | |
| Trifluoroacetic Acid SCHEMBL4325899 | 0.79 | MAP2K3 (0.54) | CNR2HTR4RORC | |
| SCHEMBL13578002 | 0.79 | CNR2 (0.53) | CNR2HTR4RORC | |
| SCHEMBL4325454 | 0.78 | SSTR4 (0.44) | CNR2SSTR4RORCCNR1 | |
| SCHEMBL13578142 | 0.77 | MAP2K3 (0.60) | CNR2HTR4RORCCNR1 | |
| Trifluoroacetic Acid SCHEMBL4341502 | 0.76 | CNR2 (0.48) | CNR2RORC | |
| SCHEMBL4325969 | 0.76 | CNR2 (0.60) | CNR2SSTR4CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2008085302-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR2 1/4885SSTR4 961/4885HTR4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.